 EMERYVILLE, Calif., July 23, 2020 GLOBE NEWSWIRE -- Adamas Pharmaceuticals, Inc. Nasdaq: ADMS today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing 833 350-1318 for participants in the U.S. or Canada and 236 738-2277 for international callers. All callers must provide the following Conference ID: 4795503. The webcast can be accessed live via the investor section of the Adamas website at and will be available for replay until November 5, 2020.About Adamas Pharmaceuticals, Inc. At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI amantadine extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit ContactInvestors: Peter Vozzo Managing Director, Westwicke 443-213-0505 Sarah Mathieson Vice President, Corporate Communications 510-450-3528 